Choosing the appropriate treatment for patients have a direct influence on each patient`s future. A doctor´s expertise, the patient´s preferences, and the current medical research have a highly influence on the choice of the treatment. Doctors shall be aware of their own decision patterns, the most influenced factors and the relevant literature by choosing the optimal patients treatments. By considering quality management and certifications, transparent representations of internal processes with simple decision-making notes are required. In support of the hypothesis, a decision analysis was conducted based on the S3 guideline for diagnosis, treatment and follow up care of breast cancer. A notation is required, which combines the process modeling and the representation of (medical) decisions.
INTRODUCTION
A transparent representation of processes is a useful gadget for physicians and other medical professionals, especially considering the requirements for quality management and certifications. Medical decisions are generally based on physicians' expertise, patients' preferences and the relevant recommendations based on the best available medical evidence. However, most decision structures are only "present in the medical experts head", which means, they are not at hand in a standardized, structured and thus "non-expert-understandable" form. The representation of decisions has been modelled in the past with The Decision Model (von Halle, Goldberg, 2009 ). In our partner clinic "Städtisches Klinikum Brandenburg GmbH" the representation of processes and decisions will be modelled mostly with Microsoft Visio. This representation has the main problem that the clarity and comprehension suffer. The Object Management Group developed the Decision Model Notation (DMN) as possibility to represent decisions transparently in an easy way of understanding and handling (Object Management Group, 2014) . Therefore this paper tries to answer the question if a representation of medical decisions with DMN is possible. Also the supporting data are required for a transparent decision representation.
MATERIAL AND METHODS

Decision Model Notation (DMN)
The Object Management Group (OMG) published in January 2014 the first Beta version of Decision Model Notation (DMN). The primary goal of this notation is design readable, understandable and transparent decision models for every kind of user.
DMN is a new standard to combine business decision design and decision implementation. Those decisions need to be analysed and represented (Object Management Group, 2014 of a decision table. Figure 1 shows the three aspects of modelling. It is very important to understand that there are two different standards for modelling decisions which are defined as followed:
 Business process modelling, using e.g. Business Process Model and Notation (BPMN).  Decision logic, which defines business rules by the way of decision tables and can be used for individual decisions. In BPMN it is possible to define business rules via the BPMN Business Rule task. This task is the link to the DMN notation. At this time there is currently no tool which combines the modelling with BPMN and DMN, except the Signavio Process Editor. The intension of DMN is to combine business process models and decisions logics (Object Management Group, 2014) . The following three aspects of modelling are relevant:
 Business process models are defining tasks in procedures, which may include decisions to be reached.  Decision requirements diagrams (DRDs) specify the kind of decision to be made and the information required. DRDs consist of different elements: the specified decision, required business knowledge, an Input-DataModel, the knowledge source and the different connectors to model the flows which combine these elements (information, knowledge and authority requirements).  Decision logics should represent the necessary decisions in such detailed manner that valid decisions in an automated fashion can be made details for validate decisions and automate the decisions also. In summery a decision structure can be represented with a Decision Requirements Diagram (DRD) and a Decision Logic. Those can be combined also with a business process model in the relevant task.
Breast Cancer -Tumour Board and Relevant Decisions
Breast cancer is the most common malignant neoplasia in females in Germany, accounted for approximately 70.000 new cases per year. After confirming the diagnosis by histopathological examination, the attending physician will inform the patient about the further steps, which follow after diagnosis. In some cases prior to this, the patient´s case will be discussed in a pre-operative tumour conference. However, according to the S3-guideline (Kreienberg et.al, 2012 ) all cases will be discussed in the postoperative tumour board. The attending physician presents the individual case to the members of the board and recommends the patient-individual treatment choices. Then the board discusses the different options and finally decides which therapeutic regiment is the most promising, based on the recommendations of the S3-guideline. This decision will take place in form of a formal consensus. The decision is then formally documented and forms the basis for the further treatment. In figure  3 this process is visualized as BPMN model. But which parameters are relevant for such a decision? According to Kreienberg et.al the patient´s age, her menopausal status, the expression of estogen and/or progesterone receptor and HER2/neu status of the tumour, Grading and the tumour and lymph node classification are required.
For this paper the systemic treatment of the patient will only be considered -consisting of either chemotherapy or endocrine therapy, a combination of both modalities, and/or the anti HER-2/neu (Human epidermal growth factor receptor 2) treatment. Based on the above listed tumour and patient related parameters according to Kreienberg R. et.al Tumour related parameters are important to describe the biology and pathology of the tumour. Gathered with patient related parameters, as the patient´s age and menopausal status, they are required to model valid DRDs. These parameters are the basement of the breast cancer treatment and they are represented as Input-Data-Model in a DRD. The most relevant knowledge source is the S3 guideline, published by the German Cancer Society. The current statements of the guideline however may be modified by other relevant literature (Kreienberg R., 2012 , Woecke A., 2010 , Wolters R, 2011 .
RESULTS
The results are represented in two major sectionsthe graphical representation of the treatment decisions for breast cancer modelled in DMN and a representation of the deduced rules in a decision table.
For a representation of the treatment in DMN three elements are required: decision element, knowledge source and Input-Data-element. The decision element will be labelled with the name "(systemic) therapy decision for breast cancer", the two Input-Dataelements will be labelled with "Tumour and Patient related parameters" and the knowledge source will be labelled with "S3 guideline". The following figure 4 shows the treatment of breast cancer in DMN. A draft of the decision logic is shown in table 1. Besides rather simples rules like: "If the patient's tumour expresses HER-2/neu, then an anti HER-2/neu antibody treatment is required" and "If an anti-HER-2/neu treatment is indicated this has to be applied simultaneously or sequentially to chemotherapy", there are a number of more or less complex rules. The example for the easy rules extending the decisions elements to: hormone receptor status (positive or negative), HER2/neu status (positive or, negative), Grading (G2, G3) and therapy (chemo-and anti HER2 therapy (CT+T), chemo-, anti HER2 and hormone therapy (CT+T+ET)). n/a n/a n/a 
CONCLUSIONS
A mandatory regarding the increasing complexity of clinical decisions as well as patient selfdetermination. This aim in our view can be achieved by modelling decision requirements diagrams using the Decision Management Notation. The representation of business rules is likewise achievable by means of defining a decision logic-therefore the decision rules must be analysed in the first instance and then represented in DMN. DMN results from a combination of Business Process Management and Decision Management (OMG, 2014) . Business Process Management is required for the transparent representation of business processes and procedures -the Business Process Model and Notation (BPMN) being one of the possibilities for modelling the processes. For the analysis of business rules a structured approach is required. According to Taylor there are four principles to be kept in mind when analysing decision rules (Taylor, 2011) . 1. Model the decisions, which are in the experts head 2. Be flexible, transparent and agile for changes 3. Be predictable 4. Combine all three rules and continue with the first task The recommendations are proven as good approach for the analysis of business rules. However, to our knowledge, there are no recent papers concerning this approach in medicine. Further work is now centred on the validation of our so far analysed and modelled decision rules. Physicians and other medical staff can benefit from transparent representation of the processes and the modelled decision rules.
